Phase 2 Study of Dacomitinib in NSCLC
Conditions: NSCLC Stage IIIB; NSCLC Stage IV; Recurrent NSCLC; EGFR Positive Non-Small Cell Lung Cancer Intervention: Drug: Dacomitinib Sponsors: National Cancer Centre, Singapore; Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Non-Small Cell Lung Cancer | Pfizer | Research | Singapore Health | Study